Association between statin exposure and risk of MPN based on the duration of statin exposure
| Subgroup . | Cases, n . | Controls, n . | OR∗ (95% CI) . | aOR† (95% CI) . |
|---|---|---|---|---|
| Exposure | ||||
| Never-use | 2484 | 12691 | 1.0 (reference) | 1.0 (reference) |
| Ever-use | 1332 | 6389 | 1.07 (0.99-1.16) | 0.87 (0.80-0.96) |
| Long-term use (≥5 y) | 658 | 3623 | 0.90 (0.81-1.00) | 0.72 (0.64-0.81) |
| Cumulative treatment duration, y | ||||
| <1 | 211 | 741 | 1.47 (1.25-1.72) | 1.15 (0.97-1.36) |
| 1-4.99 | 463 | 2025 | 1.17 (1.05-1.31) | 0.96 (0.85-1.08) |
| 5-9.99 | 369 | 1862 | 1.02 (0.90-1.15) | 0.83 (0.72-0.95) |
| ≥10 | 289 | 1761 | 0.83 (0.73-0.96) | 0.63 (0.54-0.74) |
| Subgroup . | Cases, n . | Controls, n . | OR∗ (95% CI) . | aOR† (95% CI) . |
|---|---|---|---|---|
| Exposure | ||||
| Never-use | 2484 | 12691 | 1.0 (reference) | 1.0 (reference) |
| Ever-use | 1332 | 6389 | 1.07 (0.99-1.16) | 0.87 (0.80-0.96) |
| Long-term use (≥5 y) | 658 | 3623 | 0.90 (0.81-1.00) | 0.72 (0.64-0.81) |
| Cumulative treatment duration, y | ||||
| <1 | 211 | 741 | 1.47 (1.25-1.72) | 1.15 (0.97-1.36) |
| 1-4.99 | 463 | 2025 | 1.17 (1.05-1.31) | 0.96 (0.85-1.08) |
| 5-9.99 | 369 | 1862 | 1.02 (0.90-1.15) | 0.83 (0.72-0.95) |
| ≥10 | 289 | 1761 | 0.83 (0.73-0.96) | 0.63 (0.54-0.74) |
Adjusted for age, sex, and calendar time (by matching design).
Adjusted for parameters denoted by ∗ in addition to (1) education level (primary school, high school, short/intermediate education, or long education); (2) Charlson Comorbidity Index (0, 1, or ≥2); (3) previous use of aspirin, other nonsteroidal anti-inflammatory drugs, alendronate, immunosuppressants, and metformin; and (4) previous history of alcohol-related diagnoses, overweight- and obesity-related diagnoses, chronic obstructive pulmonary disease, AD, and diabetes.